Calculator · Educational estimate

HRT Candidacy Screener

This screener follows the NAMS 2022 position statement: for most healthy women under 60 or within 10 years of menopause who have bothersome vasomotor symptoms, the benefits of hormone therapy typically outweigh the risks. It is not a substitute for a clinical evaluation.

Age (years)Years since final menstrual period (0 if not yet) (years)Bothersome hot flashes / night sweatsPersonal history of breast cancerPersonal history of blood clots (DVT/PE)Personal history of stroke or heart attackUndiagnosed vaginal bleeding

Candidacy signal

Aligned with NAMS "window of opportunity"

Age and time since menopause are within the window where the NAMS 2022 statement judges benefits of HRT to typically outweigh risks in healthy women with bothersome symptoms.

Educational estimate only. This tool does not diagnose, treat, or replace medical advice. Always confirm findings with a licensed clinician.

Related from Kindr

Questions

What is the "timing hypothesis"?

The idea, supported by ELITE and re-analyses of the WHI, that starting hormone therapy near menopause has a much more favorable benefit-risk profile than starting it 10+ years later.

Are these the only contraindications?

No. Active liver disease, some clotting disorders and other rarer conditions also affect candidacy. A clinician must review your full history.

Sources

NAMS 2022 Hormone Therapy Position Statement — www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf
ELITE trial (NEJM 2016) — www.nejm.org/doi/full/10.1056/NEJMoa1505241

Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026